Recovered Covid patients may only need single dose of Pfizer or Moderna vaccine

Nurse Sarah MacLeod, from the Vaccination Team, gives Margaret Swift, aged 69, from Balgreen, Edinburgh, her vaccine
PA
April Roach @aprilroach282 February 2021

A single dose of the Pfizer or Moderna vaccine is enough to protect people who have previously been infected with coronavirus, new research suggests.

Two studies, which have not yet been peer-reviewed, found that a single jab of the Covid-19 vaccines produced high concentrations of antibodies that often exceeded the level seen for those who are given two doses.

Experts also said that those who have previously contracted Covid-19 were more likely to report flu-like side-effects after receiving their vaccine as their immune response was re-stimulated.

The UK initially planned to leave 21 days between the first and second doses of the Pfizer vaccine, which became the first in the country to be administered to vulnerable people after it was green-lighted in early December.  

But officials moved to increase the gap between both parts of the Pfizer and Oxford-AstraZeneca vaccines to 12 weeks.

The Department of Health and Social Care said the decision to extend the wait followed a review of the data and was "in line with the recommendations of the UK's four chief medical officers".

This has proved controversial, with some groups, including the British Medical Association (BMA), calling for doses of the Pfizer jab to be given no more than six weeks apart.

Researchers at the School of Medicine at Mount Sinai New York, recruited 109 people of whom 68 were negative for previous infection and 41 had had Covid-19 before, to look at the efficacy of vaccines on those who already had the disease.

The results showed that, after a single dose, people who had been infected previously rapidly developed antibody concentrations which were 10 to 20 times higher than those without prior infection, at the same time points after the jab.

The authors said they are “providing evidence that the antibody response to the first vaccine dose in individuals with pre-existing immunity is equal to or even exceeds” that found in people without prior infection, even after the second dose.

“Changing the policy to give these individuals only one dose of vaccine would not negatively impact on their antibody titers, spare them from unnecessary pain and free up many urgently needed vaccine doses,” they wrote.

A second paper, from the University of Maryland in the US, looked at antibody responses to a single dose of the Pfizer/BioNTech or Moderna vaccines in healthcare workers who had had a positive test for Covid-19, and compared them with those who were negative for antibodies to the virus.

Overall, 59 healthcare workers were involved in the study.

Coronavirus: Home testing kits delivered

South African Virus Variant Prompts Testing Blitz
1/13

The results showed that those who had had Covid-19 previously had statistically significant higher levels of antibodies than those without, and “had a classic secondary response to a single inoculation”.

The authors concluded: “In times of vaccine shortage, and until correlates of protection are identified, our findings preliminarily suggest the following strategy as more evidence-based: a) a single dose of vaccine for patients already having had laboratory-confirmed Covid-19; and b) patients who have had laboratory-confirmed Covid-19 can be placed lower on the vaccination priority list.”

Eleanor Riley, professor of immunology and infectious disease, University of Edinburgh, said the findings from the latest studies was “very reassuring”.

“Both papers show that a previous infection with Covid-19 primes the immune system to make a very robust response to a single dose of Covid-19 vaccine,” said professor Riley.

COVID-19 vaccination of health care workers at the CHR Centre Hospitalier Regional de la Citadelle in Liege
A medical worker fills a syringe with a dose of the Pfizer-BioNTech coronavirus disease
REUTERS

“These data indicate that the vaccines are very effectively boosting the immunity induced by infection.

“The authors of both papers suggest that people who have had a PCR-confirmed Covid-19 infection may only require one dose of the vaccine.

“Certainly, this would appear to provide them with protection that is at least as good as two doses of vaccine.

“However, incorporating this into a mass vaccination programme may be logistically complex and it may be safer, overall, to ensure that everyone gets two doses.”

She pointed to the evidence suggesting that people previously infected were more likely to experience flu-like symptoms after their vaccine.

“This is good to know and will allow healthcare workers to warn people that they are more likely to feel a little off colour for a day two after their vaccination if they have previously been infected and to reassure them that this is nothing to be concerned about.”

Professor Lawrence Young, from the University of Warwick, added: “The antibody levels in previous infected individuals were rapidly elevated in response to a single vaccination reaching 10-20 times those observed in those who were vaccinated without evidence of previous infection.

“Vaccine recipients with pre-existing immunity experienced systemic side-effects with a significantly higher frequency than antibody naïve vaccines (fatigue, headache, chills, fever, muscle or joint pains).

“This suggests that the first vaccine dose is serving as a boost in naturally infected individuals, giving levels of protective immunity equivalent to that achieved with two vaccine doses in individuals who haven’t been previously infected.”

Additional reporting by PA Media.

Create a FREE account to continue reading

eros

Registration is a free and easy way to support our journalism.

Join our community where you can: comment on stories; sign up to newsletters; enter competitions and access content on our app.

Your email address

Must be at least 6 characters, include an upper and lower case character and a number

You must be at least 18 years old to create an account

* Required fields

Already have an account? SIGN IN

By clicking Create Account you confirm that your data has been entered correctly and you have read and agree to our Terms of use , Cookie policy and Privacy policy .

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged in